Alternate Day Fasting Improves Physiological and Molecular Markers of Aging in Healthy, Non-obese Humans
隔日禁食改善健康非肥胖人群衰老过程中生理标记物和分子标记物
Caloric restriction and intermittent fasting are known to prolong life- and healthspan in model organisms, while their effects on humans are less well studied. In a randomized controlled trial study (ClinicalTrials.gov identifier: NCT02673515), we show that 4weeks of strict alternate day fasting (ADF) improved markers of general health in healthy, middle-aged humans while causing a 37% calorie reduction on average. No adverse effects occurred even after >6months. ADF improved cardiovascular markers, reduced fat mass (particularly the trunk fat), improving the fat-to-lean ratio, and increased β-hydroxybutyrate, even on non-fasting days. On fasting days, the pro-aging amino-acid methionine, among others, was periodically depleted, while polyunsaturated fatty acids were elevated. We found reduced levels sICAM-1 (anage-associated inflammatory marker), low-density lipoprotein, and the metabolic regulator triiodothyronine after long-term ADF. These results shed light on the physiological impact of ADF and supports its safety. ADF could eventually become a clinically relevant intervention.
已知热量限制和间歇性禁食可以延长生物模型的生命时长和健康，但是对于它们对人类的影响研究较少。在一项随机对照试验研究中，我们发现4周的严格隔日禁食（ADF）改善了健康中年人的一般健康指标，同时平均降低了37％卡路里。在> 6个月后也没有发生不良反应。ADF这一举措（即使处于非禁食日）改善心血管疾病标志物、减少脂肪量（特别是躯干脂肪）、改善脂肪/肌肉率、并增加β-羟基丁酸盐。在禁食日，促老化氨基酸——蛋氨酸等被定期耗尽，而多不饱和脂肪酸升高。我们发现在长期ADF后，sICAM-1（一种与年龄相关的炎症标记物）、低密度脂蛋白和代谢调节剂三碘甲状腺素水平降低。这些结果揭示了ADF的生理作用并支撑其安全性。ADF最终可能成为与临床相关的干预措施。
别说能不能成为临床干预措施了，我先在我身上试验一下。
